Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 OX-IRIS first-line chemotherapy for unresectable pancreatic cancer
jRCTs011190008Phase 2Completed
- Start
- Feb 2020
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of oxaliplatin, irinotecan and tegafur in pancreatic cancer (PC). Primary endpoint: Objective response rate. Started Feb 2020; status: completed.
02
Drugs
oxaliplatinirinotecantegafur
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on jRCTs011190008.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs011190008.